医学
单克隆抗体
肾病
阻塞(统计)
阻断抗体
单克隆
抗体
内科学
免疫学
内分泌学
数学
统计
糖尿病
作者
Jonathan Barratt,Richard Lafayette,Hitoshi Suzuki,Sreelatha Melamadothil,Laura Kooeinga,Chula Herath,Muh Geot Wong,David Oldach,Asher D. Schachter,Mohit Mathur,Yusuke Suzuki
标识
DOI:10.1016/j.ekir.2024.02.258
摘要
A PRoliferation-Inducing Ligand (APRIL) is a key driver in the immune-related pathogenesis of immunoglobulin A nephropathy (IgAN). Sibeprenlimab, a humanized IgG2 monoclonal antibody that blocks APRIL, demonstrated acceptable safety with robust urine protein creatinine ratio (uPCR) reduction and eGFR stability at 12 months in a Phase 2 study of patients with IgAN.1 Defined criteria for remission in IgAN are varied and include reduction of proteinuria below certain thresholds (<1.0 g/d, <500 mg/d and <300 mg/day) as well as remission in hematuria (reduction in red blood cell [RBC] count to <5 RBC/high power field [HPF]).2–4 We report the effect of sibeprenlimab on hematuria resolution and remission of proteinuria.
科研通智能强力驱动
Strongly Powered by AbleSci AI